SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 143 filers reported holding SAGE THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $18,715,374 | -2.6% | 490,702 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $19,215,890 | +31.6% | 490,702 | +8.6% | 0.01% | +25.0% |
| Q2 2022 | $14,600,311 | -4.4% | 452,022 | -2.0% | 0.00% | +33.3% |
| Q1 2022 | $15,266,845 | -25.0% | 461,234 | -3.6% | 0.00% | -25.0% |
| Q4 2021 | $20,353,000 | -2.1% | 478,436 | +2.0% | 0.00% | -20.0% |
| Q3 2021 | $20,781,000 | -22.6% | 468,981 | -0.8% | 0.01% | -16.7% |
| Q2 2021 | $26,864,000 | +48.2% | 472,877 | +95.3% | 0.01% | +50.0% |
| Q1 2021 | $18,128,000 | -58.8% | 242,187 | -52.4% | 0.00% | -60.0% |
| Q4 2020 | $44,045,000 | +27.4% | 509,133 | -10.0% | 0.01% | +11.1% |
| Q3 2020 | $34,571,000 | +45.0% | 565,633 | -1.4% | 0.01% | +28.6% |
| Q2 2020 | $23,849,000 | +64.7% | 573,578 | +13.8% | 0.01% | +40.0% |
| Q1 2020 | $14,482,000 | -58.6% | 504,231 | +4.0% | 0.01% | -50.0% |
| Q4 2019 | $34,993,000 | -51.9% | 484,738 | -6.6% | 0.01% | -54.5% |
| Q3 2019 | $72,816,000 | -16.9% | 519,036 | +8.5% | 0.02% | -18.5% |
| Q2 2019 | $87,614,000 | +34.1% | 478,528 | +16.5% | 0.03% | +28.6% |
| Q1 2019 | $65,327,000 | +97.5% | 410,737 | +19.0% | 0.02% | +75.0% |
| Q4 2018 | $33,075,000 | -30.4% | 345,282 | +2.7% | 0.01% | -20.0% |
| Q3 2018 | $47,509,000 | +5.4% | 336,344 | +16.9% | 0.02% | 0.0% |
| Q2 2018 | $45,056,000 | +10.3% | 287,840 | +13.5% | 0.02% | 0.0% |
| Q1 2018 | $40,841,000 | -0.7% | 253,551 | +1.5% | 0.02% | 0.0% |
| Q4 2017 | $41,148,000 | +187.4% | 249,821 | +8.7% | 0.02% | +200.0% |
| Q3 2017 | $14,318,000 | -21.8% | 229,821 | 0.0% | 0.01% | -28.6% |
| Q2 2017 | $18,303,000 | +7.8% | 229,821 | -3.8% | 0.01% | 0.0% |
| Q1 2017 | $16,976,000 | +36.3% | 238,861 | -2.1% | 0.01% | +40.0% |
| Q4 2016 | $12,452,000 | +16.1% | 243,861 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $10,726,000 | +83.6% | 243,861 | +25.8% | 0.01% | +66.7% |
| Q2 2016 | $5,841,000 | -1.8% | 193,861 | +4.5% | 0.00% | 0.0% |
| Q1 2016 | $5,949,000 | -15.4% | 185,566 | +53.9% | 0.00% | 0.0% |
| Q4 2015 | $7,029,000 | +178.6% | 120,566 | +102.2% | 0.00% | +200.0% |
| Q3 2015 | $2,523,000 | – | 59,613 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |